Last reviewed · How we verify
Vincristin, Daunorubicine, Asparaginase, Methotrexate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Vincristin, Daunorubicine, Asparaginase, Methotrexate (Vincristin, Daunorubicine, Asparaginase, Methotrexate) — Gruppo Italiano Malattie EMatologiche dell'Adulto.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vincristin, Daunorubicine, Asparaginase, Methotrexate TARGET | Vincristin, Daunorubicine, Asparaginase, Methotrexate | Gruppo Italiano Malattie EMatologiche dell'Adulto | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vincristin, Daunorubicine, Asparaginase, Methotrexate CI watch — RSS
- Vincristin, Daunorubicine, Asparaginase, Methotrexate CI watch — Atom
- Vincristin, Daunorubicine, Asparaginase, Methotrexate CI watch — JSON
- Vincristin, Daunorubicine, Asparaginase, Methotrexate alone — RSS
Cite this brief
Drug Landscape (2026). Vincristin, Daunorubicine, Asparaginase, Methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/vincristin-daunorubicine-asparaginase-methotrexate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab